Atricure, Inc. (ATRC) Tops Q2 EPS by 3c, Boosts FY Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
AtriCure Reports Second Quarter 2015 Financial Results and Updates 2015 Outlook
July 28, 2015 4:02 PM EDTRevenue of $32.6 million up 22.9% as reported, 26.5% constant currency U.S. sales of $25.7 million up 29.3% International sales of $6.8 million up 3.5% as reported, 17.9% constant currency
WEST CHESTER, Ohio--(BUSINESS WIRE)-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in technologies for the surgical treatment of atrial fibrillation and left atrial appendage management, today announced second quarter 2015 financial results.
We are pleased by our results this quarter which reflect continued stability in our business and the solid foundation AtriCure is building for future growth, said... More
